Back to search results

Study of ALN-CIDEB for MASLD and MASH

This study is testing an experimental drug called ALN-CIDEB for people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). These are long-lasting liver conditions caused by too much fat in the liver. The main goal is to see how safe ALN-CIDEB is and how well people tolerate it, meaning if they experience side effects. Researchers will also look at how the drug affects liver fat and how much of the drug is in the blood. You might be able to join if you are 18 to 65 years old, have MASLD or MASH, and meet specific body mass index (BMI) and liver fat measurements. The study plans to enroll 132 participants.

Study design
This interventional study involves 132 participants who will receive either ALN-CIDEB or a placebo (an inactive substance).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for side effects for up to 48 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06836609

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Recruiting
PHASE1Ages 18–65InterventionalTreatment
Regeneron Pharmaceuticals
~132 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:ALN-CIDEBPlacebo

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Measured over Up to 48 Weeks
+1 more outcome measured

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatohepatitis

Explore related trials

Nonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis

NCT06836609

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Adobe Clinical Research

    Tucson, Arizonano site contact published

    Recruiting

  • Arizona Liver Health

    Chandler, Arizonano site contact published

    Recruiting

  • Parexel International Early Phase Clinical Unit

    Harrow, London, United Kingdomno site contact published

    Recruiting

  • Richmond Pharmacology Limited

    London, Greater London, United Kingdomno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals

Who to contact

Clinical Trials Administrator
[email protected]
844-734-6643
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of Treatment-Emergent Adverse Events (TEAEs)Up to 48 Weeks
  • Severity of TEAEsUp to 48 Weeks